Project description:We konckout PARK2 in Esophageal Squamous Cell Cancer Cell Line EC9706 and then detected differentially expressed genes We konckout PARK2 in Esophageal Squamous Cell Cancer Cell Line EC9706 and then detected differentially expressed genes
Project description:This study was designed to identify genes aberrantly expressed in esophageal squamous cell carcinoma (ESCC) cells. Three esophageal squamous cell carcinoma-derived cell lines and one normal human esophageal squamous cell line were analyzed.
Project description:Transcriptional profiling of Human Esophageal Squamous Cell Cancer Cell line (KYSE520) comparing mock transfectant (KYSE520 Mock②) with cells transfected with a mir203 expression vector (KYSE520 miR203⑥)
Project description:We analyzed ChIP-seq, chromatin accessibility and RNA-seq across mouse esophageal squamous organoids and human esophageal squamous cell cancer
Project description:We analyzed ChIP-seq, chromatin accessibility and RNA-seq across mouse esophageal squamous organoids and human esophageal squamous cell cancer
Project description:Transcriptional profiling of Human Esophageal Squamous Cell Cancer Cell line (KYSE520) comparing mock transfectant (KYSE520 Mock②) with cells transfected with a mir203 expression vector (KYSE520 miR203⑥) KYSE520 Mock② VS KYSE520 miR203⑥
Project description:Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory disease. New treatment strategies that circumvent or prevent mechanisms of resistance are needed to improve ovarian cancer therapy. We developed in vitro ovarian cancer cell line models of acquired paclitaxel resistance using 2 immortalized human ovarian cancer cell lines, OVCAR3 and TOV-21G. We also developed in vitro primary ovarian cancer organoid models using tumor tissue from 7 patients with gynecologic malignancies. Gene expression differences in resistant and sensitive lines were analyzed by RNA sequencing to identify potential mechanisms of paclitaxel resistance in primary ovarian cancer.
